| Identification | Back Directory | [Name]
Dostarlimab | [CAS]
2022215-59-2 | [Synonyms]
TSR-042
Dostarlimab
Dostarlimab (anti-PD-1)
Research Grade Dostarlimab (DHH02205) |
| Hazard Information | Back Directory | [Uses]
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1]. | [in vivo]
Dostarlimab (200 μg/mouse; i.p.; twice weekly for 35 days) shows antitumor activity in humanized mouse models[1]. | Animal Model: | Humanized NOG-EXL mice, A549 and MDA-MB-436 tumor model[1] | | Dosage: | 200 μg/mouse | | Administration: | Intraperitoneal injection; twice weekly for 35 days | | Result: | Resulted in great inhibition of tumor growth in an A549 lung cancer model (tumor growth inhibition [TGI] of 62% at termination). The antitumor activity was associated with a reduction in tumor-associated regulatory T cells and a trend toward increased tumor-infiltrating CD8+ T cells. Inhibited tumor growth of MDA-MB-436 breast cancer model (TGI of 53%).
|
| [References]
[1] Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136. DOI:10.1080/19420862.2021.1954136 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|